Replies to post #14779 on Hemispherx BioPharma (HEB)

[drkazmd65]

The price-point - especially to be delivered in a wide-spread manner in a 'developing' country (although - to be fair Brazil is relatively developed) and ease of delivery will be important factors in whether a treatment can useful AND profitable for the company that is providing that treatment.

Alferon is approved, but LDO delivery is experimental. It's an easier pathway..... not to mention a MUCH cheaper option for the large population who may need it.

I will admit to (as yet) not done the background digging on the LDO aspects and potential of HEB for Alferon,... got a link or two or reference you might point me to in order to let me get started more efficiently Johnny?

Regardless of whether it might be Alferon or Ampligen that could be use to push HEB forward,.... Management actually needs to get off their behinds and get the work done to get the job done. That's more the end of this company where I start to get concerned.

The science may be fine,.... their execution of an actual business plan leaves something to be desired.